If you've spent any time researching GLP-1 medications for weight loss, you've seen the two names that dominate the conversation: semaglutide and tirzepatide. They're the most studied, most prescribed, and most effective weight management medications currently available. They're also often confused with each other, which is understandable, because they look similar on the surface.

But they aren't the same medication, and the difference matters. One targets a single receptor. The other targets two. One has been studied for longer. The other produces greater average weight loss in clinical trials. Both can cause similar side effects. Both can be life-changing. And the right choice depends on more than just which one has the bigger number next to it.

Here's what the evidence actually shows in 2026, and how to think about choosing between them.

The short answer

In the first direct head-to-head clinical trial (SURMOUNT-5, published in the New England Journal of Medicine in May 2025), tirzepatide produced more weight loss than semaglutide on average: 20.2% of body weight versus 13.7% over 72 weeks. That's a meaningful difference, but it isn't the whole picture. Side effects, cost, insurance coverage, your health history, how your body responds, and how your provider thinks about your case all factor in. Many people do extremely well on semaglutide. Many others benefit more from tirzepatide's dual-action mechanism. The decision should be made with a licensed provider who knows your full medical picture, not from a blog post alone.

With that said, let's look at what's actually going on.

How they work: one receptor versus two

Both medications belong to a class called incretin-based therapies. They mimic hormones your body naturally produces after you eat. These hormones help regulate appetite, slow stomach emptying, and signal fullness to your brain. But they target slightly different sets of receptors, and that's where the differences begin.

Semaglutide: single-target GLP-1

Semaglutide mimics one gut hormone: glucagon-like peptide-1, or GLP-1. When the medication binds to GLP-1 receptors, several things happen. Your brain receives signals that you're full, sooner and for longer. Your stomach empties more slowly, which extends the feeling of satiety after meals. Insulin secretion improves in response to food. Cravings, especially for high-calorie, high-reward foods, tend to decrease.

Semaglutide has been in widespread clinical use since 2017 for type 2 diabetes, and since 2021 as an obesity treatment. It's the most studied GLP-1 medication in the world, with years of real-world and clinical trial data behind it.

Tirzepatide: dual-target GLP-1 and GIP

Tirzepatide does everything semaglutide does, and also activates a second receptor: glucose-dependent insulinotropic polypeptide, or GIP. GIP is another gut hormone, and its receptor is found not only in the pancreas but also in fat cells, where it appears to play a role in how the body stores and mobilizes fat.

The clinical hypothesis behind dual-action medications like tirzepatide is straightforward. Activating two incretin pathways simultaneously produces additive effects on appetite and fat metabolism that a single-pathway drug can't match. The data has largely supported that hypothesis. Tirzepatide was approved by the FDA for chronic weight management in late 2023 (under the brand name Zepbound), and it's quickly become the most-studied newer entrant in this space.

Head-to-head: what SURMOUNT-5 actually showed

For years, the semaglutide-versus-tirzepatide conversation had to rely on indirect comparisons. Each drug was tested in its own trials, with different patient populations and different designs, so clinicians had to extrapolate. That changed with SURMOUNT-5, the first randomized, controlled trial to compare the two drugs head-to-head in adults with obesity.

Here's what the trial looked like. 751 adults with obesity (or overweight with at least one weight-related comorbidity) and without type 2 diabetes were randomized 1:1 to the maximum tolerated dose of either tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg), once weekly. Treatment ran for 72 weeks. The primary endpoint was percent change in body weight.

The results, published in the New England Journal of Medicine, were consistent enough that the clinicians running the trial weren't surprised:

Average weight loss at 72 weeks: tirzepatide 20.2%, semaglutide 13.7%. Participants losing 25% or more of body weight: tirzepatide 31.6%, semaglutide 16.1%. Participants losing 20% or more: tirzepatide approximately 52%, semaglutide approximately 32%.

Tirzepatide produced roughly 47% greater relative weight loss than semaglutide. The benefit held across subgroups: men and women, older and younger, higher and lower starting BMI. In absolute terms, a 200-pound person taking tirzepatide lost about 40 pounds on average; on semaglutide, about 27 pounds.

Important context: SURMOUNT-5 tested branded Zepbound versus branded Wegovy, the FDA-approved versions of these medications. Results from the branded trials are the best available data on how these active ingredients behave in the body, but individual results vary significantly based on adherence, diet, activity, genetics, and other factors.

Side effects: remarkably similar, with one surprise

A reasonable assumption would be that the more potent drug produces more severe side effects. The data doesn't really support that.

Both medications share the same core side-effect profile, primarily gastrointestinal, especially during dose escalation. The most common are nausea, vomiting, diarrhea, constipation, decreased appetite (intended, but sometimes uncomfortable), and fatigue, particularly in the first few weeks.

These symptoms typically peak during dose increases and improve as the body adjusts. Most are mild to moderate. Serious side effects (pancreatitis, gallbladder issues, and in rare cases, thyroid concerns) carry the same FDA warnings for both medications.

The surprise: in SURMOUNT-5 and related studies, tirzepatide actually showed slightly lower rates of nausea, vomiting, and diarrhea than semaglutide in several categories. The leading explanation is that the GIP component may buffer some of the GI effects that come from pure GLP-1 activation. For people who've struggled with semaglutide side effects, this is clinically relevant.

One other point worth noting. Both medications lead to weight loss that's largely fat mass (around 83 to 85%), with the rest being lean tissue. That's in line with what happens with significant weight loss from any cause, including diet and exercise, and it's why protein intake and resistance training matter on these medications.

Dosing: how you'd actually take them

Both medications are taken as a once-weekly subcutaneous injection, usually in the abdomen, thigh, or upper arm, using a fine needle similar to what people with diabetes use for insulin. Both require a gradual dose escalation over several months to minimize side effects.

Semaglutide typically starts at 0.25 mg weekly and increases every four weeks: 0.5 mg, then 1 mg, then 1.7 mg, then 2.4 mg (the maintenance dose for weight management). The full escalation usually takes 16 to 20 weeks.

Tirzepatide starts at 2.5 mg weekly and escalates every four weeks: 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg. Full escalation is typically 20 weeks.

Your provider will adjust the pace of escalation based on how you're tolerating the medication. Some people reach full dose quickly. Others plateau at a mid-range dose that's working well for them.

Cost: the branded versus compounded reality

Brand-name GLP-1 medications are expensive. Out of pocket, Wegovy (branded semaglutide) runs approximately \$1,300 to \$1,350 per month. Zepbound (branded tirzepatide) runs approximately \$1,060 to \$1,350 per month.

Insurance coverage varies widely. Many plans don't cover these medications for obesity indications. Some plans only cover them after failed trials of other interventions. Prior authorization is often required.

Compounded versions, medications prepared by licensed 503A compounding pharmacies based on an individual prescription, have become a significant part of the landscape, particularly for patients without coverage. Compounded medications are not FDA-approved and are prepared pursuant to a valid prescription from a licensed provider for a specific patient. Pricing varies by provider, but compounded options are typically a fraction of the branded cost.

At CLYR, our compounded formulations include Vitamin B12 to support energy and metabolism during weight loss, and pricing is transparent with no hidden fees.

Who might be a better fit for each?

There's no universal answer, but there are patterns that providers weigh.

Tirzepatide often makes sense when a patient has a higher starting BMI and wants to maximize weight loss potential; when a patient has struggled with GI side effects on semaglutide in the past; when a patient has insulin resistance or metabolic dysfunction (though both drugs help here); or when a patient has tried semaglutide and hit a plateau below their goal.

Semaglutide often makes sense when a patient wants the medication with the longest track record for weight management; when a patient's weight loss goals are moderate and achievable at that dose range; when a patient has cardiovascular disease history (semaglutide has established cardiovascular outcome data from the SELECT trial); or when a patient responds well and tolerates the medication without issue. There's no reason to switch from something that's working.

Both can be appropriate when a patient has never tried a GLP-1 before, with the decision driven by cost, tolerability, provider judgment, and patient preference; when a patient is transitioning between medications based on availability, insurance, or response; or when a patient has PCOS, fatty liver disease, or other metabolic conditions where either medication has been shown to help.

The honest answer: your provider should decide with you

The internet has a tendency to frame these comparisons as "X is better than Y, period." The actual clinical picture is more nuanced. SURMOUNT-5 shows tirzepatide produces more weight loss on average, but averages don't apply to individuals. Plenty of people do exceptionally well on semaglutide. Plenty of people on tirzepatide would have done almost as well on semaglutide at a lower cost. And plenty of people are candidates for neither because of contraindications a provider needs to evaluate.

That's the whole point of a legitimate telehealth provider relationship. A real licensed clinician reviews your full medical history, current medications, family history, lab markers (when indicated), and weight loss goals before recommending a medication, and stays involved as your treatment progresses. Not a 30-second quiz. Not an algorithm. A provider.

Frequently asked questions

Is tirzepatide always better than semaglutide? On average, tirzepatide produces greater weight loss in clinical trials. But "better" depends on the individual. Cost, tolerability, medical history, and how your body responds all matter. Many people achieve their goals on semaglutide.

Can you switch from semaglutide to tirzepatide? Yes, many patients do, typically under a provider's guidance and with a re-escalation to a new starting dose. Switching isn't a simple dose swap; the two medications have different dose ranges and potencies.

Do semaglutide and tirzepatide have the same side effects? The profile is very similar, mostly gastrointestinal, most intense during dose escalation, improving over time. Tirzepatide shows slightly lower rates of certain GI effects in trial data, possibly due to its GIP component.

How are compounded semaglutide and tirzepatide regulated? Compounded medications are prepared by licensed 503A compounding pharmacies pursuant to valid prescriptions. They are not FDA-approved as finished products, and oversight differs from branded drugs. Choosing a LegitScript-certified telehealth provider, working with licensed 503A pharmacies, and being evaluated by a real licensed provider are the key signals of a responsible compounded treatment program.

How long do I need to stay on semaglutide or tirzepatide? Obesity is considered a chronic condition, and these medications are generally most effective when taken long-term. Research shows that stopping treatment often leads to weight regain over time. Duration decisions should be made with your provider based on your goals, response, and overall health.

Can I lose weight without either of these medications? Yes, many people do, through sustainable dietary and lifestyle changes. GLP-1 medications are tools, not magic, and they work best alongside nutrition, movement, sleep, and stress management. For some patients with obesity, however, the biology makes lifestyle changes alone insufficient, which is where these medications earn their place in modern obesity medicine.

The Bottom Line

SURMOUNT-5 was the first randomized trial to compare semaglutide and tirzepatide head-to-head. The result: tirzepatide produced about 47% more weight loss on average, with similar (and in some cases slightly milder) side effects. But the right medication for any individual depends on cost, medical history, response, and goals, not the trial average. That decision belongs with a licensed provider, not a blog post.

If you're considering compounded semaglutide or tirzepatide, CLYR Health offers both options starting at \$149 per month on a 6-month plan (semaglutide) and \$225 per month (tirzepatide), including a licensed provider consultation, Vitamin B12, and priority shipping. Start your assessment at /intake.html.